Singapore markets closed
  • Straits Times Index

    3,157.13
    -9.81 (-0.31%)
     
  • S&P 500

    4,395.26
    -23.89 (-0.54%)
     
  • Dow

    34,935.47
    -149.03 (-0.42%)
     
  • Nasdaq

    14,672.68
    -105.62 (-0.71%)
     
  • BTC-USD

    39,499.77
    -2,376.93 (-5.68%)
     
  • CMC Crypto 200

    961.88
    +11.98 (+1.26%)
     
  • FTSE 100

    7,096.79
    +64.49 (+0.92%)
     
  • Gold

    1,810.00
    -7.20 (-0.40%)
     
  • Crude Oil

    73.14
    -0.81 (-1.10%)
     
  • 10-Yr Bond

    1.2390
    0.0000 (0.00%)
     
  • Nikkei

    27,781.02
    +497.43 (+1.82%)
     
  • Hang Seng

    26,235.80
    +274.77 (+1.06%)
     
  • FTSE Bursa Malaysia

    1,493.00
    -1.60 (-0.11%)
     
  • Jakarta Composite Index

    6,096.54
    +26.50 (+0.44%)
     
  • PSE Index

    6,446.31
    +176.08 (+2.81%)
     

MedinCell’s Long-Acting Injectable to Fight Malaria Ready to Enter Regulatory Development

·2-min read

MedinCell and the project consortium members, IRD, IRSS and CIRDES, have successfully designed, tested, and confirmed with Unitaid the selection of the lead formulation. Regulatory preclinical activities are starting with the objective of a first clinical trial in 2023.

MONTPELLIER, France, Jun 14, 2021--(BUSINESS WIRE)--MedinCell and the consortium members have conducted an in vivo proof of concept on cattle that showed a 3-month mosquitocidal effectiveness of an injectable long-acting formulation of Ivermectin based on the proprietary BEPO® technology.

The investigational product mdc-STM aims at reducing the transmission of the parasite responsible for Malaria, thanks to a killing effect on the vector mosquitoes when they bite treated people.

Malaria remains one of the main health threats worldwide with more than 200 million people infected yearly.

In March 2020, global health agency Unitaid granted MedinCell with a $6.4 million subvention over three years to conduct the formulation and preclinical activities of the program.

mdc-STM benefits from synergies with other MedinCell’s programs based on Ivermectin all of them using different formulation and doses fitted to their specific indications.

Access the complete press release.

About MedinCell

MedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e. compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO® technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. Based in Montpellier, MedinCell currently employs more than 140 people representing over 25 different nationalities.

www.medincell.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20210614005689/en/

Contacts

MedinCell
David Heuzé
Head of communication
david.heuze@medincell.com
+33 (0)6 83 25 21 86

NewCap
Louis-Victor Delouvrier
Relations investisseurs
medincell@newcap.eu
+33 (0)1 44 71 94 94

NewCap
Nicolas Merigeau
Media Relations
medincell@newcap.eu
+33 (0)1 44 71 94 94

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting